Lumida
/MRVI
⌘K
Maravai LifeSciences Holdings Inc

Maravai LifeSciences Holdings Inc

MRVI
$7.24USD↑+2.12%+0.15 today

MARKET CAP

1.9B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $7

52W RANGE

$2
$7

AI Summary

Stalk
StalkMedium

MRVI remains in a clear Stage 2 advance with strong higher highs and higher lows, supported by steeply rising short-term EMAs and constructive volume. However, price is extended well above the 9/21/50 EMA zone with extreme overbought conditions, reducing immediate entry viability. Medium-term bias stays bullish underpinned by the active Parabola acceleration and intact trend structure, but heightened reversal risk demands patience. Execution should be deferred into pullbacks to the rising EMA support area. Primary risks include abrupt reversals from acceleration extremes, failure of EMAs to hold support, and potential Stage 2→3 transition if exhaustion intensifies.

  • ↑Q1 2026 revenue $65.8M (+41% YoY), TriLink up 65%.
  • ↑Free cash flow $4.2M positive, first since Q3 2024.
  • ↓Negative earnings yield and weak profitability factors persist.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Maravai Life Sciences, Inc. (NASDAQ: MRVI) is a prominent player in the biotechnology sector specializing in nucleic acid production and biologics safety testing. The company’s key segments, TriLink and Cygnus, focus on innovative solutions tied to high-demand areas such as gene therapy and personalized medicine, aligning with the ongoing advancements in mRNA technologies. Maravai's strategic position within the life sciences value chain and its recent innovations position it well to capitalize on emerging opportunities in the biotech landscape post-COVID-19.

Bull says

  • ↑Q1 2026 revenue $65.8M (+41% YoY), TriLink up 65%.
  • ↑Free cash flow $4.2M positive, first since Q3 2024.
  • ↑Raised 2026 revenue guidance to $205–215M (10–16% growth).
  • ↑Adj. EBITDA $20.3M and gross margin up >1,300bps.
  • ↑Launch of IVT kits taps mRNA and gene therapy demand.
  • ↑High analysts’ revisions score and 0.63% dividend yield.

Bear says

  • ↓Negative earnings yield and weak profitability factors persist.
  • ↓Negative growth factors signal potential revenue slowdown.
  • ↓$242.9M long-term debt heightens leverage and interest risk.
  • ↓Customer concentration and distributor ordering volatility threaten revenue.
  • ↓Declining institutional ownership indicates waning investor confidence.
  • ↓Low book-to-price and cash management issues deter investors.

Investment themes with MRVI

Health Care Services↑ +0.30%

HIMS · WAY · CON

Earnings Call · Q3 2024 · Mgmt. Guidance

Updated 05-31-2026neutral

Transcript signals

Bull points

  • We remain committed to advancing the field by playing a key role in the development of mRNA-based in vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines. Flanders II codifies this commitment to our customers through phase three and commercial production.
  • The fact that this customer chose to be the very first in our new facility is a testament to their confidence in our team's capabilities, expertise, and commitment to high quality, and we are delivering on all fronts.
  • we believe we are the innovation leader and well-positioned to service the growing segments of mRNA therapeutics discovery and development.

Bear points

  • Q3 results were slightly below our expectations, primarily due to a few customer-requested program timing shifts, muted demand in research and discovery products within our NAP businesses, and persistent softness in the global biologics market, which impacted our BST segment.
  • our Q3 2024 revenues were $65 million, slightly below our expectations for the quarter.
  • Both business segments lagged our expectations with the NAP segment impacted by softer clean cap demand in both RUO and GMP businesses, as well as a custom-requested delay of a preclinical program bill.
Read full transcript analysis ›